Journal ArticleOPEN ACCESS

Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer

Molecular Therapy Oncolytics (2020) 19 57-66
DOI: 10.1016/j.omto.2020.08.020
22Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

TG6002 is a double-deleted vaccinia virus expressing FCU1 that converts 5-fluorocytosine into 5-fluorouracil. This study demonstrates oncolytic properties of TG6602 in 2D and 3D cultured canine mammary cell lines, in a xenograft model, and in canine mammary tumor explants. Moreover, it establishes 5-fluorouracil production in fresh canine tumor biopsies.

Author supplied keywords

Cite

CITATION STYLE

APA

Béguin, J., Foloppe, J., Maurey, C., Laloy, E., Hortelano, J., Nourtier, V., … Erbs, P. (2020). Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer. Molecular Therapy Oncolytics, 19, 57–66. https://doi.org/10.1016/j.omto.2020.08.020

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free